Update on Medicare Coverage for Avastin (bevacizumab)

Months ago, we told you about a Medicare contractor who was denying coverage of Avastin for patients with ovarian cancer. The Ovarian Cancer National Alliance has worked with Members of Congress and Centers for Medicare and Medicaid Services (CMS) to change this reimbursement policy.

OCNA worked with Partner Members, patients, family members and elected officials from the affected area – Oklahoma, New Mexico, Colorado and Texas – to advocate for adherence to the law.  One Senator and 42 Members of the House of Representatives wrote to CMS.  OCNA met with CMS General Counsel and continued applying pressure on the agency in numerous formats.

This week, the Ovarian Cancer National Alliance learned that the Medicare contractor denying coverage for Avastin has reversed its previous decision and will pay for Avastin for women with epithelial ovarian cancer. This is a great win for the ovarian cancer community.